Abstract
Resveratrol, a natural product most famously present in red wine, has been in the headlines for a decade, ever since scientists reported that it activates a pathway linked to antiaging effects. Whether and how the molecule elicits those effects is a controversial topic, however. And as efforts progress to make drugs that mimic resveratrol’s actions the, debate has heightened. A new study shows that a much-maligned approach for finding resveratrol mimics—an essential task for confirming the antiaging mechanism—actually does work (Science, DOI: 10.1126/science.1231097). The study was carried out by researchers with a significant financial stake in making resveratrol-like drugs, a group led by David A. Sinclair of Harvard Medical School. Coauthors include researchers from Sirtris Pharmaceuticals, the company Sinclair cofounded to combat cardiovascular, neurodegenerative, and other diseases of aging, and from GlaxoSmithKline, which bought Sirtris for $720 million in 2008. Sinclair and others believe resverat...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
